Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Prometheus Test for Crohn's Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories today announced the New York State Department of Health has approved its proprietary Prometheus Crohn's Prognostic test for sale.

The test, which is performed in Prometheus' CLIA lab, combines six serologic markers and three genetic mutation markers and provides doctors with a personalized serologic profile for patients, the San Diego-based specialty pharmaceutical and diagnostics firm said. As a result, doctors can quantify patient risk for developing complications over time and determine appropriate treatments for patients.

In North America, between 400,000 and 600,000 people are affected by Crohn's disease, Prometheus said.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.